XENE Company Profile and Key Details

Q: Who are the executives of XENE?

Ms. Sherry AulinChief Financial OfficerMs. Shelley McCloskey B.A.Executive Vice President of HRMs. Sheila M. Grant M.B.A., M.Sc., MBAExecutive Vice President of R&D OperationsMr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBAPres, Chief Executive Officer & DirectorDr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy & InnovationDr. James R. Empfield Ph.D.Executive Vice President of Drug DiscoveryMs. Jodi Regts M.B.A., B.A., MBAVice President of Corporation Affairs & Investor RelationsDr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.Chief Commercial OfficerMs. Andrea DiFabio J.D.Chief Legal Officer & Corporation Sec.Dr. Christopher John Kenney M.D.Chief Medical OfficerMr. Ian C. Mortimer C.M.A., C.P.A., CMA, CPA, M.B.A., MBAPres, Chief Executive Officer & Director

NASDAQ : XENE

Xenon Pharmaceuticals

$57.40

1.27+2.26%

At Close 4:00 PM

59.27

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Xenon Pharmaceuticals Inc. (XENE) stock surged +2.26%, trading at $57.40 on NASDAQ, up from the previous close of $56.13. The stock opened at $55.86, fluctuating between $55.86 and $58.49 in the recent session.

Stock Snapshot

56.13

Prev. Close

4.53B

Market Cap

55.86

Day Low

-13.17

P/E Ratio

-4.36

EPS (TTM)

-2.13

Cash Flow per Share

55.86

Open

78.95M

Number of Shares

58.49

Day High

92.85%

Free Float in %

13.26

Book Value

777.9K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	55.86	58.49	55.86	57.40	777.9K
Apr 30, 2026	55.70	56.86	55.24	56.04	1.34M
Apr 29, 2026	53.89	56.91	53.80	55.75	1.7M
Apr 28, 2026	54.85	55.53	53.30	54.53	728.99K
Apr 27, 2026	55.03	56.21	54.02	54.26	693.93K
Apr 23, 2026	56.65	57.51	55.24	55.41	613.37K
Apr 22, 2026	56.73	57.90	56.25	56.65	716.14K
Apr 21, 2026	56.48	57.00	55.66	56.40	652.96K
Apr 20, 2026	59.57	59.68	56.90	57.09	1.12M
Apr 17, 2026	59.47	59.87	58.65	59.70	870.13K
Apr 16, 2026	58.88	58.88	57.82	58.43	976.85K
Apr 14, 2026	58.29	59.99	58.24	59.35	851.48K
Apr 13, 2026	58.52	59.90	57.64	58.60	498.4K
Apr 10, 2026	58.45	58.91	57.87	58.40	635K
Apr 09, 2026	57.68	58.94	57.44	58.59	764.47K
Apr 08, 2026	59.14	59.42	56.67	57.54	699.74K
Apr 07, 2026	56.69	57.70	55.85	57.65	667.64K
Apr 06, 2026	57.14	57.85	56.41	56.84	1.65M
Apr 02, 2026	56.00	57.44	55.86	56.85	897.23K
Apr 01, 2026	58.54	59.44	56.42	56.69	1.38M

Contact Details

Burnaby, BC V5G 4W8

Canada

https://www.xenon-pharma.com 160 448 43300

About Company

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) closed at $57.40 USD, gaining $1.27 (2.26%) from the previous close of $56.13. The stock is currently mid-range between its 52-week high and low $28.19 and $63.95. With a market capitalization of about $4.53 billion, Xenon Pharmaceuticals Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.74). Key stats such as the average daily volume over the past year has been around 1.41 million shares, volume is running light vs its 52-week average. Headquartered in Burnaby, BC, Xenon Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrea DiFabio, the company employs approximately 316 people and listed since November 05, 2014. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

Technical Performance

XENE has shown mixed momentum, gaining 0.63% over the past week and -0.34% over the past quarter, though year-to-date performance is down -7.43%. Short-term trend indicators are mixed aligned (SMA20 6.11%, SMA50 5.59%, SMA200 18.27%). The stock’s 14-day RSI is 62.92 (firm momentum), while the ATR of 1.61 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.61% below its high and over 67.99% above its low. Average 10-day trading volume of 1.05 million shares is below the 3-month average of 1.42 million, indicating normal recent market interest.

Valuation Metrics

Xenon Pharmaceuticals Inc. trades at a P/E ratio of -13.21, slightly below the S&P 500 average, with a price-to-sales ratio of 607.05 and a price-to-book ratio of 7.86 trading at moderately above to book value. The P/FCF stands at -16.27, also below market averages.

Dividend & Fair Value

Xenon Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.34. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Xenon Pharmaceuticals Inc. generated EPS of -$3.88 over the past year. Five-year average earnings growth is -14.28%. Wall Street analysts project EPS growth of -13.97% annually over the next five years. The latest quarter delivered EPS of -$1.31. The next quarter is forecast at -$1.19. Next year's EPS is expected at -$17.64. Analyst sentiment is bullish. Analyst rating data shows there are 15 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $97.00 to $43.00. The high target offers 68.99% upside. The low target suggests -25.09% downside. The mean target is $60.95. This offers 6.18% upside. Xenon Pharmaceuticals Inc. earnings surprise history is a mixed track record. The quarter that ended February 26, 2026, missed forecasts by 9.17%. The prior quarter beat by -1.12%. Over the last six quarters, Apple has recorded several small beats. These include -1.22% in November 12, 2024.

Shareholding & Insider Activity

Xenon Pharmaceuticals Inc. has 77.11 million shares outstanding. The public float is 71.60 million shares, elevated short interest at 9.99% of float. This equals 6.91 million shares. The short ratio is 7.33 days. Institutional investors hold 95.43% of the float. Insiders own 0.11%. BVF PARTNERS L P/IL holds 1.08 million shares, Hayden Michael R has 161.19 thousand shares and HOLLER FRANK A has 143.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 106.90 thousand shares across 11 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Xenon Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -18.90% and ROE at -19.66%.
On valuation metrics, Xenon Pharmaceuticals trades at a P/E of -13.21, P/S of 607.05 and P/B of 7.86. The current ratio is 13.42 and quick ratio is 13.42. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 48.61 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -35.14.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Xenon Pharmaceuticals posted revenue of $0.00, down slightly from $9.43M in the prior quarter. Gross profit was - $3.54M (margin 0.00%). Operating income was - $214.05M (margin 0.0%). Net income was- $182.39M (EPS - $2.73).
The company ended the quarter with $638.08M in cash and short-term investments, a total debt of $10.90M, and net debt of - $137.74M. Total assets were $964.80M, with equity of $927.92M. Financials further reflected weakness, with operating cash flow of - $145.33M, free cash flow of - $150.94M, and capital expenditures of - $5.62M.

Price Forecast & Outlook

Our AI price prediction model suggests that Xenon Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.03%, with price expected at $53.94 by May 18, 2026, within a range of $51.99 to $55.81 3-Month Outlook: Projected rise of 68.83%, reaching $96.91 by July 31, 2026, with a range of $95.64 to $98.95. 1-Year Outlook: Projected gain of 2.11%, with price at $58.61 by May 04, 2027, within a range of $57.08 to $60.92.

Key Takeaways

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares are flat -7.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Xenon Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of -13.21. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $49.98, suggesting -12.93% downside. Our AI forecast model points to short-term weakness (-6.03% over two weeks), a medium-term rise (68.83% over three months), and a longer-term gain (2.11% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Xenon Pharmaceuticals Inc. (XENE) stock price?

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) stock price is $57.40 in the last trading session. During the trading session, XENE stock reached the peak price of $58.49 while $55.86 was the lowest point it dropped to. The percentage change in XENE stock occurred in the recent session was 2.26% while the dollar amount for the price change in XENE stock was $1.27.

XENE's industry and sector of operation?

The NASDAQ listed XENE is part of Biotechnology industry that operates in the broader Healthcare sector. Xenon Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of XENE?

Ms. Sherry Aulin
Chief Financial Officer
Ms. Shelley McCloskey B.A.
Executive Vice President of HR
Ms. Sheila M. Grant M.B.A., M.Sc., MBA
Executive Vice President of R&D Operations
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Pres, Chief Executive Officer & Director
Dr. Robin P. Sherrington Ph.D.
Executive Vice President of Strategy & Innovation
Dr. James R. Empfield Ph.D.
Executive Vice President of Drug Discovery
Ms. Jodi Regts M.B.A., B.A., MBA
Vice President of Corporation Affairs & Investor Relations
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.
Chief Commercial Officer
Ms. Andrea DiFabio J.D.
Chief Legal Officer & Corporation Sec.
Dr. Christopher John Kenney M.D.
Chief Medical Officer
Mr. Ian C. Mortimer C.M.A., C.P.A., CMA, CPA, M.B.A., MBA
Pres, Chief Executive Officer & Director

How XENE did perform over past 52-week?

XENE's closing price is 103.62% higher than its 52-week low of $28.19 where as its distance from 52-week high of $63.95 is -10.24%.

How many employees does XENE have?

Number of XENE employees currently stands at 316.

Link for XENE official website?

Official Website of XENE is: https://www.xenon-pharma.com

How do I contact XENE?

XENE could be contacted at phone 160 448 43300 and can also be accessed through its website. XENE operates from 3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.

How many shares of XENE are traded daily?

XENE stock volume for the day was 777.9K shares. The average number of XENE shares traded daily for last 3 months was 1.41M.

What is the market cap of XENE currently?

The market value of XENE currently stands at $4.53B with its latest stock price at $57.40 and 78.95M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	316
Beta	0.94
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

XENE Company Profile and Key Details

Xenon Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook